Sort
10,766 grants matching “checkpoint inhibitor”
Investigating multifactorial beta-catenin activation in hepatocellular cancers
$511,819Xin Chen · University Of California, San Francisco · R01 · FY2021 · CA
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
$511,800Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2024 · CA
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ
$511,747Robert C Rostomily · Methodist Hospital Research Institute · R01 · FY2024 · NS
Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate Cancer
$511,680Lawrence Fong · University Of California, San Francisco · P50 · FY2024 · CA
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$511,570Lajos Pusztai · Yale University · R01 · FY2019 · CA
Investigating a new vulnerability in oral squamous cell carcinoma
$511,509Christine M Eischen · Thomas Jefferson University · R01 · FY2024 · DE
Targeting replication stress to engage DNA sensing STING pathway derived anti-tumor immunity to improve the therapeutic outcomes in uterine cancer
$511,431Jean Zhao · Dana-Farber Cancer Inst · P01 · FY2024 · CA
Dissecting the role of Notch signaling in the pancreatic cancer microenvironment.
$511,394Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Interrogating the response of the tumor microenvironment to combination immunotherapy using a microfluidic platform
$511,345Albert Folch · University Of Washington · R01 · FY2024 · CA
Project-003
$511,159Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2019 · CA
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
$511,114Justin M Balko · Vanderbilt University Medical Center · R01 · FY2023 · CA
Lysophosphatidic Acid Regulation of CD8 T cell activation and function
$510,922Raul Martin Torres · University Of Colorado Denver · R01 · FY2020 · AI
Lysophosphatidic Acid Regulation of CD8 T cell activation and function
$510,922Raul Martin Torres · University Of Colorado Denver · R01 · FY2024 · AI
Lysophosphatidic Acid Regulation of CD8 T cell activation and function
$510,922Raul Martin Torres · University Of Colorado Denver · R01 · FY2022 · AI
Lysophosphatidic Acid Regulation of CD8 T cell activation and function
$510,922Raul Martin Torres · University Of Colorado Denver · R01 · FY2023 · AI
Lysophosphatidic Acid Regulation of CD8 T cell activation and function
$510,922Raul Martin Torres · University Of Colorado Denver · R01 · FY2021 · AI
Targeting PP4 to improve ovarian cancer response to immunotherapy
$510,892Marion Curtis · Mayo Clinic Arizona · R37 · FY2023 · CA
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow
$510,637Geoffrey Roger Hill · Fred Hutchinson Cancer Center · P01 · FY2023 · CA
Sustaining Tissue Resident Memory T cells
$510,630Yina Hsing Huang · Dartmouth College · R01 · FY2024 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$510,440Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$510,440Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2022 · CA
The Adenosinergic Pathway in Tumor-derived Exosomes
$510,187Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Clinical protocols for the treatment of gastrointestinal cancer
$510,185Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Understanding the impact of chemotherapy on breast cancer metastasis and immune function in the liver
$510,175Sandra S McAllister · Brigham And Women'S Hospital · R01 · FY2023 · CA
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
$510,000Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2021 · HL